DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for galactosialidosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGalactosialidosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for galactosialidosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cathepsin A (CTSA) — CTSA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cyclohexylmethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4CIB · 1.89 Å · ligand 2-(cyclohexylmethyl)propanedioic acid (7UZ). Experimental structure, not a prediction.
What the evidence adds up to
Plasma chitotriosidase activity was more than 150 times the normal median value in two galactosialidosis patients, according to a 2004 survey of disorders with elevated activity of that enzyme. No other drug or intervention was tested in that report.
A 1988 case described a 19-year-old white male with juvenile galactosialidosis who had hip arthralgia, facial coarseness, corneal clouding, mitral and aortic insufficiency, and hepatosplenomegaly. Fibroblast enzyme analysis showed low activities of both alpha-neuraminidase and beta-galactosidase. Unlike most previously reported Japanese patients, this patient did not have macular cherry-red spots, neurologic abnormalities, or mental retardation. The authors speculated the case represented a new subtype with a potentially different molecular defect.
A 2010 report on three patients with adult-form galactosialidosis described diffuse fine opacities in the deep corneal stroma, an obscure cherry-red spot of the macula, and optic nerve atrophy in all three. Two patients had punctate lenticular opacities. All three had slowly progressive visual disturbance, which the authors attributed to secondary optic nerve atrophy from retinal ganglion cell death. No treatment was administered or evaluated.
No controlled trial, no drug intervention, and no survival or response-rate data exist in these abstracts. What is missing is any clinical trial testing a therapy, any patient stratification by molecular defect, and the funding needed to move from case reports to interventional studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Inherited Metabolic Disease · 2004 · 68 citations · open access
The expanding spectrum of disorders with elevated plasma chitotriosidase activity:An update
AbstractA striking elevation of plasma chitotriosidase activity, greater than 150 times the normal median value, was found in two galactosialidosis patients. Furthermore, increased plasma chitotriosidase activity, 10-53 times the normal median value, was also observed in fucosidosis, glycogen storage disease type IV, Alagille syndrome and hydrops fetalis due to congenital herpes virus infection.
American Journal of Medical Genetics · 1988 · 15 citations
Juvenile galactosialidosis in a white male: A new variant
AbstractWe describe a 19-year-old white male with juvenile galactosialidosis. He presented with hip arthralgia and was found to have facial "coarseness," corneal clouding, mitral and aortic insufficiency, and hepatosplenomegaly. Ultrastructural studies of skin biopsy and peripheral blood lymphocytes showed membrane-bound inclusions containing sparse fibrillogranular material. Biochemical analysis showed elevated urinary sialyloligosaccharides and no free sialic acid. Fibroblast enzyme analysis showed low activities of both alpha-neuraminidase and beta-galactosidase. To date, most patients with juvenile galactosialidosis have been Japanese. However, unlike those patients, our patient did not have macular cherry-red spots, neurologic abnormalities, or mental retardation. We speculate that this young man represents a new subtype of juvenile galactosialidosis with a potentially different molecular defect from that of the Japanese variant.
Adult-Form Galactosialidosis: Ocular Findings in Three Cases
AbstractWe reported ocular findings of 3 patients with adult-form galactosialidosis. Diffuse fine opacities in the deep layer of the corneal stroma, an obscure cherry-red spot of the macula and optic nerve atrophy were noted in all cases. Punctate lenticular opacities were observed in 2 cases. Slowly progressive visual disturbance was seen in all cases, and it might be due to secondary optic nerve atrophy caused by retinal ganglion cell death.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
